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A B S T R A C T
Objective: Evaluation of the clinical effectiveness and safety of a new custom-made valgus knee brace
(OdrA) in medial knee osteoarthritis (OA) in terms of pain and secondary symptoms.
Methods: Open-label prospective study of patients with symptomatic medial knee OA with clinical
evaluation at 6 and 52 weeks (W6, W52). We systematically assessed pain on a visual analog scale (VAS),
Knee injury and Osteoarthritis Outcome Score (KOOS), spatio-temporal gait variables, use of
nonsteroidal anti-inﬂammatory drugs (NSAIDs) and analgesic-sparing effects of the brace and tolerance.
Mean scores were compared at baseline, W6 and W52 and the effect size (ES) and 95% conﬁdence
intervals (95% CIs) were calculated.
Results: We included 20 patients with knee OA (mean age 64.2  10.2 years, mean body mass index
27.2  5.4 kg/m2). VAS pain and KOOS were improved at W6 and W52: pain (ES = 0.9 at 1 year), amelioration
of other symptoms (ES = 0.4), and function in activities of daily living (ES = 1.1), sports and leisure (ES = 1.5),
quality of life (ES = 0.9) and gait speed (ES = 0.41). In total, 76% of patients showed clinical improvement at
1 year. Analgesic and NSAIDs consumption was signiﬁcantly decreased at W6 and W52. One serious adverse
effect noted was lower-limb varices, and observance was deemed satisfactory at 1 year.
Conclusion: This new unloader brace appeared to have good effect on medial knee OA, with an acceptable
safety proﬁle and good patient compliance.
 2015 Elsevier Masson SAS. All rights reserved.
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Knee osteoarthritis (OA) is a chronic disabling joint disease that
causes increasingly severe functional impairment in everyday
activities. The medial compartment is the most frequently affected,
given the physiological high loading on this zone. The condition is
frequently aggravated by constitutional or acquired bow-legged-
ness [1,2]. To limit pain in medial-compartment knee OA,
conservative medical management combining pharmacological
and nonpharmacological treatment is recommended [3–5]. The
use of medical devices such as foot pronation orthotics [6,7] or
articulated valgus knee braces is advocated [8–10]. Although the* Corresponding author. Rheumatology department, Dijon University Hospital,
14, rue Gaffarel, 21000 Dijon, France. Tel.: +33 3802 937 45; fax: +33 3802 93678.
E-mail address: paul.ornetti@chu-dijon.fr (P. Ornetti).
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1877-0657/ 2015 Elsevier Masson SAS. All rights reserved.beneﬁcial effect of these devices on symptoms are related to their
proprioceptive properties [11,12] or muscle activation [13–15], the
principal effect stems from their ability to unload the medial
compartment, where the pain originates [1,2,8,16–18].
The improvement in functional capacities is better with
unloader knee braces than knee sleeves or neutral articulated
braces [8,16,19,20]. However, the efﬁcacy of the braces is still
debated [10,21,22], and tolerance to the braces is poor because
they irritate the skin, impair venous return, can cause oedema and
are bulky, which can hamper certain movements in everyday life
[23]. In clinical practice, this type of orthotic device is rarely
prescribed by physicians specialized in degenerative joint diseases
of the knee because they prefer pharmacological treatments and/or
rehabilitation [8].
Recently, the PROTEOR group developed a new custom-made
brace, the OdrA system (Fig. 1). The brace features an innovative
system to unload the medial compartment by distraction and
Fig. 1. Knee brace with the OdrA system (PROTEOR, France).
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axis of the ground reaction force vector backwards and medially
toward the center of the knee joint, which reduces the knee
adduction moment during the propulsion phase but disappears in
the swing phase or at rest, with the knee bent. The new system,
which was recently validated biomechanically in terms of kinetic
and kinematic dimensions [24], is also less cumbersome because
it is custom-made, with few voluminous tibial and femoral straps.
This dynamic unloader brace, with no effect at rest with the knee
bent, is equipped with a rack and pinion system that plays a dual
role in weight-bearing positions: distraction and external
rotation of the leg. The effect is to shift the centre of the load
toward the natural inter-condyle position and thus to limit
overloading of the medial compartment [24], which is often
aggravated in patients with bow-leggedness or with medial
meniscus degeneration.
In terms of the current overall re-evaluation of treatments in
knee OA, the beneﬁcial effects of this device on symptoms by
unloading the medial compartment as well as tolerance and
compliance could lead to its use in clinical practice. However, in
addition to data needed from validated algo-functional ques-
tionnaires, spatio-temporal gait data are needed to provide an
objective evaluation of the functional beneﬁts of this dynamic knee
brace on gait [18,25,26]. These investigations are in response to
recent requests from accreditation organisations responsible for
authorising the commercialisation of these medical devices: the
French health authority requires a high level of scientiﬁc evidence
for these orthotic devices, with high-quality therapeutic trials, on
which marketing approval for these expensive and not risk-free
devices depends [27].
The primary objective of this interventional prospective single-
centre study was to evaluate the efﬁcacy of the new valgus knee
brace with the OdrA system for medial-compartment knee OA on
pain at week 6 (W6). Secondary objectives were to evaluate the
effect of the brace on other symptoms in the short-term (W6) and
medium-term (W52) and to provide data on tolerance and
compliance in clinical practice.2. Materials and methods
2.1. Patients
Patients consulting at the Department of Rheumatology and
Physical Medicine of Dijon University Hospital over six months
were recruited consecutively. We included patients 40 to 80 years
old who had unilateral medial-compartment knee OA according
to ACR criteria [28] (medial compartment pain at rest > 4 on a 0–
10 visual analog scale [VAS]), radiological stage II, III or IV
according to the Kellgren and Lawrence classiﬁcation [29]
determined by radiography performed in the previous six months,
with no change in pharmacological treatment in the previous six
months and no injections of hyaluronic acid or corticosteroids
during this period. Exclusion criteria were presence of a disease
that could interfere with gait analysis or inﬂammatory or rapidly
destructive knee OA. Patients with an indication for surgery
according to the medical specialist consulted, a valgus morpho-
type or another disease likely to cause knee pain or modify gait
were also excluded. After inclusion and custom-moulding of the
OdrA brace, patients were instructed to wear the brace for at least
6 h/day, 5 days/week.
The study was conducted in accordance with good clinical
practices and the Declaration of Helsinki (ClinicalTrials.gov
identiﬁer: NCT01884883) and was approved by the local ethics
committee. Patients gave informed consent to be in the trial.
2.2. Gait protocol
At inclusion and at W6 after wearing the brace, patients
underwent a standard protocol for quantiﬁed gait analysis (VICON
system, Oxford, UK). This gait protocol has been described
elsewhere for the biomechanical validation of the OdrA device
[24]. Brieﬂy, reﬂective markers, detected by eight infrared cameras,
were placed on the pelvis and lower limbs of patients, who were
instructed to walk up and down a 10-m path 12 times. The spatio-
temporal gait variables were recorded over the 6 m in the middle of
the track to avoid acceleration and deceleration phenomena. The
patients were told to walk at their usual comfortable speed.
2.3. Data collection
At inclusion, the following clinical data were collected: age, sex,
body mass index (kg/m2), disease duration, and radiological stage
by the Kellgren and Lawrence classiﬁcation [29].
Judgement criteria were collected at inclusion and at 6 and
52 weeks (W6, W52). For the principal outcome criteria
(improvement in pain at W6 compared with inclusion), pain
was measured at rest by a VAS (0–100).
The following secondary outcomes were evaluated. Improve-
ment in pain at W52 compared with at inclusion was measured at
rest by a VAS (0–100). Overall self-evaluation of disease severity
was measured by a VAS (0–100). Function was measured by the
Knee injury and Osteoarthritis Outcome Score (KOOS) consisting of
42 questions covering 5 domains, each scored from 0 (worst) to
100 (best) [30]: pain, other symptoms, function in activities of
daily living (ADL), function in sports and leisure (SL) activities and
quality of life (QoL). This internationally validated score includes
all of the domains of Western Ontario and McMaster Universities
Arthritis Index (WOMAC; pain, stiffness, function) and adds more
demanding activities and important aspects of QoL. The KOOS can
be represented in the form of a graph, with a line linking the
different domains [31]. Consumption of nonsteroidal anti-inﬂam-
matory drugs (NSAIDs) and analgesics was evaluated by the
number of days per week each class of drug was taken. Disease
severity at W6 and W52 was measured by a semi-quantitative
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improved; 5, much improved. Tolerance to the brace and
compliance was evaluated by recording adverse effects in a
patient diary and by mean time the brace was worn (number of
hours per day and number of days per week). The following spatio-
temporal gait variables were collected at W0 and W6 [24]: walking
speed (m/s), stride length (m), stride width (m), stride frequency
(Hz), single and double support time (% of gait cycle) and step
dephasing (% of gait cycle).
2.4. Statistical analysis
The principal analysis was intent-to-treat (ITT), with last
observation carried forward (LOCF) used for missing data. Data are
described with mean  SD for clinical and gait spatio-temporal
variables. Scores at different times were compared with those at
inclusion by Wilcoxon matched pairs test. P < 0.05 was considered
statistically signiﬁcant. The amplitude of the therapeutic effect of the
brace for each judgement criterion was evaluated by the effect size
(ES) with the following interpretation: 0 to 0.5, weak effect; 0.5 to 0.8,
moderate effect; > 0.8, major effect [32]. For ES values (clinical and
spatio-temporal parameters), 95% conﬁdence intervals (95% CIs) were
calculated by the non-parametric bootstrap method.
According to data in the literature from similar clinical studies,
improvement in pain on a VAS at W6 (principal criterion) should be
at least 20%. With an alpha risk of 0.05 and power of 80%, a
minimum of 15 subjects was necessary. Taking into account the
possibility of patients leaving the trial, we needed to include
20 patients for 1 year of follow-up. Statistical analysis involved use
of Statistica v10.2 (Statsoft Inc., Tulsa, USA).
3. Results
We included 20 patients in the study (16 females; mean age
64.2  10.2 years; mean body mass index 27.2  5.4 kg/m2) (Table 1).
Pain, disease severity and functional disability at inclusion were high,
with no indication for surgery according to the treating rheumatolo-
gist. In total, 16 patients (80%) were taking level I or II analgesics and
6 (30%) NSAIDs. At W6, clinical and gait analysis data were analyzed
for 19 patients because one patient had to stop wearing the brace
due to venous intolerance and at W52, 18 of the 19 patients were
re-evaluated (one patient lost to follow-up).Table 1
Characteristics of the 20 patients wearing the OdrA brace for knee osteoarthritis
(OA) at inclusion.
Characteristics
Age (years) 64.2  10.2
Sex ratio (F/M), no. of patients 16/4
BMI (kg/m2) 27.2  5.4
Disease duration (years) 6.4  4.7
Pain, VAS (0–100) 63.1  12.8
Disease severity, VAS (0–100) 64.2  16.5
WOMAC function (0–100) 56.7  12.8
Symptomatic treatments (% patients)
Analgesics 80
NSAIDs 30
SYSADOAs 35
Radiographic stage of knee OA
Kellgren and Lawrence classiﬁcation, no. of patients
II 5
III 9
IV 6
Data are mean  SD unless indicated.
BMI: body mass index; VAS: visual analog scale; WOMAC: Western Ontario and
McMaster University Osteoarthritis Index; NSAIDs: nonsteroidal anti-inﬂammatory
drugs; SYSADOAs: symptomatic slow-acting drugs.At W6, mean pain score had decreased by more than 50% from
inclusion (63.1  12.8 to 29.8  14.2, P < 0.001) (Table 2; Fig. 1). The
ES at W6 was 2.6 (95% CI 1.6–2.6); the mean pain score was
38.1  17.4 at W52 (ES 2.1 [1.0–2.8]). A signiﬁcant beneﬁt was also
seen for functional repercussions at W6 (P < 0.01, ES > 1), whatever
the KOOS domain: pain (ES 1.9 [1.5–2.5]); other symptoms (ES
1.2 [0.4–2.0]); function ADL (ES 1.8 [1.4–2.2]); function SL (ES
1.7 [1.2–2.2]); and QoL (ES 1.1 [0.3–1.9]). At W52, this beneﬁt on
symptoms remained signiﬁcant as compared with at inclusion for all
domains (Fig. 2).
However, the domains of pain, symptoms and function ADL
were signiﬁcantly decreased between W6 and W52. At W6, 85% of
patients thought that their state with regard to knee OA had
‘‘improved’’ or ‘‘much improved’’ as compared with 76% at W52.
The consumption of NSAIDs and analgesics had decreased
signiﬁcantly at W6 and W52 (P < 0.05). At W52, the consumption
of analgesics had decreased to a mean of 1.3 days per week as
compared with 4.5 at inclusion, and one third of patients had
stopped analgesics completely. For NSAIDs, of the six patients who
were taking these at least once a week, only one continued to take
them regularly at W52. Concerning professional activities, for
those who had not retired (40% of professionally active patients at
inclusion), two of the three patients on sick leave because of knee
OA were able to go back to work part- or full-time at W52.
Concerning the gait analysis (Table 3), between inclusion and
W6, walking speed increased because of a concomitant increase in
stride length and frequency. Walking speed had increased by a
mean of 10% between inclusion and ﬁnal evaluations (ES 0.41 [95%
CI 0.06–0.75], P < 0.05) and exceeded 1 m/s, considered appropri-
ate for people in this age group. Stride length increased to a lesser
degree (ES 0.25 [0.09–0.51]). In contrast, stride width, step
dephasing and single and double support time were not
signiﬁcantly modiﬁed by wearing the brace. The ES for objective
gait variables (0.16–0.45) was smaller than that for subjective
clinical parameters.
Concerning device tolerance, one female patient had to stop the
study early because of aggravation of lower-limb varicose veins,
although Doppler ultrasonography revealed no deep vein throm-
bosis. Six patients reported one or several superﬁcial adverse
effects concerning the skin: local heat (n = 2), moderate irritation
(n = 4), and zone of excessive weight bearing at the front of the tibia
(n = 5). The patients wore the knee brace for a mean of >8 h/day
and > 6 days/week at W6, with a decrease to a mean of 6 h/day and
4.7 days/week at W52. Most patients reported no particular
difﬁculties in putting on and taking off the brace, but some
reported difﬁculties in getting dressed (n = 5) because of the lateral
hinges.
4. Discussion
The results of this clinical evaluation of a new valgus knee brace,
the OdrA, for which the biomechanical properties have already
been validated [24], show that the brace effectively reduced
symptoms of medial-compartment knee OA, in both the short-
term (ES at W6 from 1.1 [95% CI 0.3–1.9] to 2.6 [1.6–2.6]) and the
medium-term (ES at W52 from 0.9 [0.3–1.5] to 1.9 [1.0–2.8])
according to KOOS scores. These results are better than those
reported in the literature (ES 0.2–0.7) for unloader braces used by
other patients with symptomatic knee OA [16,26,33–35]. This
improvement is superior to the minimal clinically important
difference (MCID) reported for the KOOS (37). However, this
threshold (MCID 9/100), which depends on patient characteristics,
is recognized only for the KOOS QoL [36] and function in ADL [37]
and is equivalent to the MCID for the WOMAC function subscale in
knee OA [38].
Table 2
Clinical scores at inclusion (W0), 6 weeks (W6) and 1 year (W52) after wearing the OdrA knee brace and magnitude of the therapeutic effect (effect size).
Clinical variables W0
n = 20
W6
n = 19
W52
n = 18
ES (95% CI)
W6 W52
Pain, VAS (0–100) 63.1  12.8 29.8  14.2* 38.1  17.4*§ 2.6 (1.6–3.6) 1.9 (1.0–2.8)
Disease severity, VAS (0-100) 64.2  16.5 34.1  16.8* 36.9  15.9*§ 1.9 (1.1–2.7) 1.7 (1.0–2.4)
KOOS (0–100)
Pain 42.6  12.5 66.0  13.6* 54.3  13.2*§ 1.9 (1.4–2.4) 0.9 (0.5–1.3)
Symptoms 54.4  17.3 75.7  17.5* 60.2  16.2*§ 1.2 (0.4–2.0) 0.4 (0.05–0.9)
ADL 44.5  12.6 67.8  11.9* 58.5  12.7*§ 1.8 (1.4–2.2) 1.1 (0.6–1.6)
SL 14.5  13.4 37.3  12.9* 34.0  12.4* 1.7 (1.2–2.2) 1.5 (0.7–2.2)
QoL 28.6  17.4 45.9  23.3* 45.7  16.5* 1.0 (0.3–1.7) 0.9 (0.3–1.5)
Data are mean  SD unless indicated.
KOOS: Knee injury and Osteoarthritis Outcome Score (0–100, 0, worst, to 100, best); ADL: activities of daily living; SL: sport and leisure activities; QoL: quality of life; ES: effect size;
95% CI: 95% conﬁdence interval.
*P < 0.05 comparing W6 vs W0 and W52 vs W0.
§P < 0.05 comparing W6 vs W52.
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with lower-limb varicose veins, which may be a contraindication
for this type of semi-rigid knee support. The brace seems to be
relatively easy to use in everyday life, even in older patients, and
thus has few of the constraints frequently reported with this type
of apparatus concerning putting it on or the bulkiness [23].
Our study contains some limitations. The recruitment at a
teaching hospital implies bias in the selection of patients with
symptomatic knee OA. As well, the study had a small sample size,
which could have hidden signiﬁcant differences and did not allow
us to identify predictors of a good response by multivariate
analysis for deﬁning the proﬁle of patients. Therefore, the results
need to be conﬁrmed in larger studies. The possible placebo effect,
which is well known in OA [39], also needs to be considered in this
evaluation of beneﬁts of the brace for symptoms. The results were
still positive at one year and compliance was good, which suggests
that the effect on symptoms was substantial; rates of pain relief
with these medical devices often decrease quickly in the medium-
term [40]. Only a randomised study comparing a neutral placebo
brace could estimate the part of pain relief related to the placebo
effect. A comparative randomised study comparing a reference
articulated unloader knee brace already on the market could have
been proposed to overcome this weakness, but such an analysis
could not be realized in this preliminary study.
Pain and function were substantially improved with the brace,
as shown by the ES (>0.8) and the high rate of satisfaction amongFig. 2. Knee injury and Osteoarthritis Outcome Score (KOOS) proﬁle for patients wearing
(W52, n = 18). ADL: activities of daily living; SL: sports and leisure activities; QoL: quapatients (>75% at one year). The reduced consumption of drugs
achieved by wearing the brace is important; this judgement
criterion is rarely reported for these braces (one negative study for
NSAIDs and analgesics and two positive studies [19,20,41]). This
latter point is of clinical relevance for this disease, with disability
implications for everyday life activities, and for OA patients, who
are often older and taking a large number of drugs. Concerning the
clinical follow-up at one year, two of the three patients on sick
leave at inclusion were able to return to work and nine patients
who had stopped physical activities (sport and/or leisure) were
able to resume them. Wearing the brace was accompanied by
improved QoL, as was previously reported with this type of
apparatus [34], and underlines the importance of taking this
pertinent judgement criterion into account. It also justiﬁes
choosing the KOOS rather than the Lequesne or WOMAC
assessment, because this recently validated international score
evaluates more demanding activities (running, squatting) and
addresses interesting aspects of QoL [30]. In the literature, only one
study used the KOOS [42] but did not show the beneﬁts of an
articulated valgus brace compared with a brace in a neutral
position. In our sample, the efﬁcacy of the brace seemed to wane
with time, especially for everyday symptoms, which could have
been due to a deterioration in the arthritis or to the less frequent
use of the brace after one year, as shown by patient diaries, or
perhaps premature wear of the unloader brace, which will have to
be proven. Indeed, this type of custom-made device may need the OdrA knee brace at inclusion (W0, n = 20) and week 6 (W6, n = 19) and week 52
lity of life. *P < 0.05 for W6 vs W0 and W52 vs W0. P < 0.05 for W6 vs W52.
Table 3
Spatio-temporal gait variables at inclusion (W0) and 6 weeks (W6) after wearing
the OdrA knee brace and magnitude of the therapeutic effect (effect size).
Gait variables W0
n = 20
W6
n = 19
ES
(95% CI)
Walking speed (m.s1) 0.98  0.24 1.08  0.26* 0.41 (0.06–0.75)
Stride length (m) 1.08  0.20 1.13  0.21* 0.25 (0.09–0.51)
Frequency (cycle/min1) 53.4  6.6 56.4  7.2* 0.45 (0.13–0.77)
Single-support time
(% gait cycle)
66.3  2.5 65.9  2.7 0.16 (0.12–0.20)
Double-support time
(% gait cycle)
15.3  2.5 14.8  1.6 0.20 (0.02–0.38)
Step dephasing
(% gait cycle)
51  0.6 51.1  0.6 0.16 (0.13–0.19)
Stride width (m) 0.28  0.05 0.29  0.06 0.20 (0.08–0.32)
Data are mean  SD unless indicated.
ES, effect size; 95% CI, 95% conﬁdence interval.
*P < 0.05 comparing W6 and W0.
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patient (three patients in our series). Thus, to achieve its
biomechanical effect properly, the custom-made brace must ﬁt
the contours of the limb perfectly.
Several studies have used the WOMAC (included in the KOOS)
to assess the effect of a valgus knee brace. Most reported a
signiﬁcant improvement in symptoms, although with an
ES < 0.8 in the most recent review of the literature [18]. Nonethe-
less, these data are difﬁcult to compare because the populations
were heterogeneous and the articulated braces did not all have the
same degree of valgisation or the same unloader mechanism. For
example, none used the dynamic external rotation effect of the
OdrA system [24]. Therefore, the exact place of valgus braces and
the characteristics of the population that could beneﬁt from them
have yet to be established in medial knee OA, despite the recent
scientiﬁc interest in these devices [3,10]. We now need well-
conducted studies with reference follow-up criteria, such as
validated questionnaires [20] and/or the analysis of reference
quantiﬁed gait parameters [43,44] in knee OA.
Most of our spatio-temporal gait variables showed signiﬁcantly
improvement but to a lower degree than for pain and function
variables. This lower ES (0.16–0.45, depending on the variable) for
objective criteria compared with subjective patient-reported
outcomes may be explained in part by a greater inter-subject
variability in these biomechanical criteria. The ﬁndings also raise
the possibility of a placebo effect induced by wearing the brace. We
found a fast (in six weeks) and signiﬁcant increase (>10%) in speed,
which corroborates certain results with other articulated knee
braces, for example, for the absence of any effect on stride width
[12,18]. Several hypotheses could explain this more efﬁcient gait,
the ﬁrst being a postural gain due to the improved proprioception
with the custom-made knee brace [11,45] but above all, the
unloader effect on the medial compartment of the affected side,
which is inversely associated with walking-related pain in knee OA
[2,8,14,42].
Altogether, the new valgus brace with the OdrA system appears
to have a beneﬁt/risk ratio that is better than those reported so far
with the reference unloader braces, or three-point braces. These
results will be re-evaluated in the near future in a French
multicentre randomized real-life study, conducted at the request
of the French Health Authority, with both algo-functional and
medico-economics criteria (cost-utility analysis). This study will
allow for better determining the place of this new medical device
in the therapeutic management of knee OA [5,10]. These prelimi-
nary results conﬁrm the place of valgus braces in medial-
compartment knee OA [46], as underlined by the new OARSI
recommendations [4].Disclosure of interest
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